Is it practical for medical practices to retain only stellar employees and pay them well above other practices, while letting one-fourth to one-fifth of their workforce go every year, to be replaced by new workers who will hopefully prove to be stellar? Would it be consistent with the culture of medical practices to reproduce the Netflix system of “high performance”?
The Affordable Care Act will affect ophthalmologists and their patients in the upcoming years.
Several new refractive surgical platforms have been introduced recently, and many ophthalmologists are discovering they find the new technologies to be more efficient and produce better results.
The goal of restoring accommodation in presbyopic eyes with femtosecond laser treatment seems to be getting closer.
The future of treatment for diabetic macular edema is likely to include a wider range of treatment options, improved efficacy, and the possibility of disease prevention.
With modern techniques and recent innovations, adjustable suture strabismus surgery can be performed in nearly all pediatric and adult cases, provided that ophthalmologists have had sufficient training.
Ocular oncologists are using enhanced depth imaging-optical coherence tomography to identify and learn about choroidal tumors.
Nowhere does it state in staff contracts that they have to like everyone, but they will work together professionally and kindly.
The 2014 version of Current Procedural Terminology contains two important changes for ophthalmologists who provide glaucoma services.
According to recent study results, transepithelial photorefractive keratectomy is a better alternative procedure than other refractive methods when treating myopia that involves epithelium mechanical manipulation.
Corneal astigmatism may be reduced or nearly eliminated after intrastromal femtosecond laser astigmatic keratotomy.
The natural history of diabetic retinopathy is modified by long-term treatment with intravitreal ranibizumab, relates one ophthalmologist.
Calculating intraocular lens (IOL) powers has become simpler and more accurate in eyes with long and short axial lengths with use of intraoperative aberrometry and an optimized method of regression analysis.
Results of a study comparing matched groups of eyes undergoing myopic correction by small-incision lenticule extraction (SMILE) or LASIK show that the optical quality was better and the cornea retained higher tensile strength after the flapless SMILE procedure.
The refractive surgical decision tree is augmented by a new option for topography-guided custom ablation.
Intracorneal ring surgery, when combined with an optical coherence tomography-guided femtosecond laser, will be a boon to centers providing high-volume LASIK and keratoconus treatment, relates one surgeon.
Preliminary 1-year data highlight patient satisfaction; dry eye can be problematic for some
A Bascom Palmer Eye Institute (BPEI) research team has pioneered a novel technology treatment for Leber Hereditary Optic Neuropathy (LHON).
The FDA has granted final approval for Hi-Tech Pharmacal Co. Inc.’s Abbreviated New Drug Application for its bromfenac ophthalmic solution, 0.09% (once-a-day).
The future of treating Fuchs’ endothelial dystrophy may be evolving, said Gerrit R.J. Melles, MD, PhD.
Rapid Pathogen Screening Inc. (RPS) has received a Medical Device License from Health Canada for its AdenoPlus, a point-of-care test to help quickly and accurately determine whether a conjunctivitis infection is caused by Adenovirus.
Regeneron Pharmaceuticals and Bayer HealthCare have announced an agreement to jointly develop an innovative antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a potential combination therapy with aflibercept (Eylea) for the treatment of wet age-related macular degeneration (AMD).
An international panel of ophthalmologists have developed a classification system of vitreomacular diseases, with the goals of objectivity based on optical coherence tomography (OCT) findings and ease of use.
OASIS Medical Inc. and Spain-based AJL Ophthalmic SA have announced an exclusive relationship for the sales and distribution of corneal implants (Intacs) for the treatment of keratoconus and the FDA-approved treatment of myopia.
Nicox Inc. has been granted the North American promotional rights to Sequenom Laboratories’ RetnaGene AMD laboratory-developed test for the evaluation of a patient’s risk of age-related macular degeneration (AMD) disease progression within 2, 5, and 10 years.
Numerous reports show that phacoemulsification lowers IOP, but further research is needed to understand what mediates the change, according to Douglas J. Rhee, MD.
Ocular Therapeutix has received approval from the FDA to commercialize its ReSure Sealant in the United States, with an indication for prevention of postoperative fluid egress from incisions with a demonstrated would leak following cataract surgery.
Carl Zeiss Meditec AG has acquired-through its subsidiary Carl Zeiss Meditic Inc.-100% of the shares in Aaren Scientific Inc., a US-based manufacturer of IOLs.
Regeneron Pharmaceuticals and Geisinger Health System have announced a major research collaboration focused on studying the genetic determinants of human disease.
.png "Optometry Times"){kind=logo}
